Akili Interactive Labs

Founded in 2011 by Eddie Martucci, Adam Gazzaley, Matt Omernick, and PureTech Health, Boston-based Akili Interactive Labs develops clinically validated digital therapeutics that utilize video game technology to treat cognitive impairments like ADHD. The digital medicine company created EndeavorRx, the first FDA-cleared prescription video game treatment for pediatric ADHD, while establishing strategic partnerships with recognizable entities including Pfizer Inc. and Autism Speaks. Before going public via a 2022 merger with Social Capital Suvretta Holdings Corp. at a $1 billion pro forma enterprise value, the organization secured over $300 million in private funding. Akili initially operated under a prescription healthcare model before launching EndeavorOTC and transitioning to a direct-to-consumer subscription approach, which was accompanied by a workforce reduction. Following this strategic pivot, the business was acquired and taken private by Virtual Therapeutics for approximately $34 million in 2024.

# Akili Interactive Labs: High-Level Overview

Akili Interactive Labs is a digital therapeutics company that develops prescription video game treatments for cognitive impairments, primarily ADHD.[1][2] Founded in 2011 and headquartered in Boston, Massachusetts, the company combines neuroscience with interactive entertainment to deliver clinically validated treatments through engaging mobile games rather than traditional pharmaceuticals.[3] The company went public through a SPAC merger in August 2022 and has raised over $300 million in funding.[2]

Akili serves patients—particularly children and adults—diagnosed with attention-deficit/hyperactivity disorder (ADHD) and other cognitive impairments by offering software-based medicine that improves attention and focus through personalized, adaptive gameplay.[7] The company solves a critical problem in neuropsychiatric treatment: poor patient compliance and engagement with traditional therapies. By making treatment enjoyable, Akili increases adherence while delivering measurable cognitive improvements, addressing a significant gap in how cognitive disorders are currently managed.

# Origin Story

Akili Interactive was founded in 2011 by a team that recognized an opportunity at the intersection of cognitive neuroscience, consumer technology, and game design.[1] The company's founding insight was elegant: if treatment could be made engaging and fun—particularly for children—it could dramatically improve compliance and outcomes. This led to the development of EndeavorRx, which became the first FDA-authorized video game treatment for ADHD in children ages 8–12, receiving FDA clearance in June 2020.[2]

The company's trajectory accelerated significantly with clinical validation. Akili completed 20 clinical trials across 2,900 patients and nine disease populations, with findings published in 16 peer-reviewed journals.[3] This rigorous scientific foundation distinguished Akili from typical gaming companies and positioned it as a legitimate pharmaceutical alternative. The $1 billion SPAC deal in August 2022 represented a pivotal moment, validating the digital therapeutics category and bringing Akili to public markets.[2]

# Core Differentiators

• Proprietary Technology Platform: Akili's Selective Stimulus Management Engine (SSME™) is specifically designed to target neural systems involved in attentional control through closed-loop, personalized algorithms that adapt to individual patient needs.[3] This represents a patented, clinically validated approach unavailable from competitors.

• Clinical Rigor & Regulatory Validation: Unlike most gaming companies, Akili has FDA clearance for prescription use (EndeavorRx for children) and over-the-counter approval (EndeavorOTC for adults).[5][7] The company's 20 completed clinical trials and peer-reviewed publications establish credibility that traditional game developers cannot match.

• Dual Product Strategy: Akili operates both prescription and over-the-counter offerings, expanding addressable market from diagnosed patients requiring medical oversight to broader populations seeking cognitive enhancement without prescription barriers.[5][7]

• Entertainment-Grade User Experience: Treatments are delivered through high-end interactive action video games that feel like premium entertainment products, not medical software, driving engagement and compliance—particularly critical for pediatric populations.[3][6]

• Scalable Digital Delivery: Unlike pharmaceutical treatments requiring manufacturing, distribution, and pharmacy networks, Akili's products scale through app stores and digital channels, reducing friction and enabling rapid geographic expansion.[7]

# Role in the Broader Tech Landscape

Akili operates at the convergence of three powerful trends: the digital health revolution, the gamification of wellness, and the shift toward preventive and personalized medicine. The company is pioneering the "digital therapeutics" category—software-based treatments that compete directly with pharmaceutical interventions by targeting the underlying neurobiology of cognitive disorders.

The timing is particularly favorable. ADHD diagnoses continue rising globally, yet traditional treatments (stimulant medications) face compliance challenges, side effects, and stigma. Simultaneously, mobile gaming has achieved mainstream acceptance and sophistication, making game-based medicine culturally viable in ways it wasn't a decade ago. Regulatory bodies like the FDA are increasingly comfortable with software-as-medicine frameworks, as evidenced by Akili's clearances.

Akili's influence extends beyond its own products. By demonstrating that video games can deliver measurable clinical outcomes, the company has validated an entirely new category for venture capital, pharmaceutical companies, and healthcare systems. This has accelerated investment in digital therapeutics broadly and challenged the pharmaceutical industry's traditional drug development model. The company's public market presence signals to investors and healthcare providers that digital medicine is not a niche experiment but a legitimate, scalable business model.

# Quick Take & Future Outlook

Akili stands at an inflection point. The company has proven clinical efficacy and regulatory validation, but faces the challenge of scaling adoption within healthcare systems accustomed to traditional pharmaceuticals. Key questions ahead include: Can Akili expand beyond ADHD into the nine disease populations in its pipeline? Will healthcare payers (insurance companies, government programs) reimburse digital therapeutics at scale? Can the company maintain its scientific credibility while operating as a public company under earnings pressure?

The broader trend favoring Akili is clear: healthcare is moving toward personalized, data-driven, software-enabled treatments. As cognitive health becomes increasingly recognized as critical to quality of life—and as traditional pharmaceutical approaches face limitations—companies like Akili that combine rigorous neuroscience with engaging technology will likely capture significant market share. The next phase will determine whether Akili becomes the category leader or one of many digital therapeutics competitors. Either way, the company has already reshaped how medicine can be delivered, proving that effective treatment need not come in a pill bottle.